Submucosal Uterine Fibroid in Grand Multipara Woman: A Case Report

Authors

  • Muhammad Rusda Department of Obstetrics and Gynecology, Endocrinology Reproductive Division, School of Medicine, Universitas Sumatera Utara, Medan, Indonesia
  • Arvitamuriany Triyanthi Lubis Department of Obstetrics and Gynecology, Endocrinology Reproductive Division, School of Medicine, Universitas Sumatera Utara, Medan, Indonesia
  • Muhammad Ramadhan Hisworo Department of Obstetrics and Gynecology, Endocrinology Reproductive Division, School of Medicine, Universitas Sumatera Utara, Medan, Indonesia https://orcid.org/0000-0002-2268-6838
  • Andrina Yunita Murni Rambe Department of Otorhinolaryngology, School of Medicine, Universitas Sumatera Utara, Medan, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2021.6317

Keywords:

Uterine fibroid, Submucous fibroid, Grand multiparous

Abstract

Background: to report and analyze a case that diagnosed with submocous uterine fibroid in grand multiparity woman.

Methods: Case Report

Case: a 49 years woman, P7A0 came with chief complaints vaginal bleeding that has been experienced since one year ago getting worse in 2 months. Her general condition was within normal limit and there was no abnormality in physical examination, by vaginal examination there was blood in the vagina, origin from the External Uterine Orificium (EUO),bimanual examination showed anteflexion uterus with normal size, right and left adnexa within normal limits. From transvaginal ultrasound we found submucous uterine fibroid size 3 x 3 cm, we decided to perform Total Abdominal Hysterectomy.

Conclusion: Hysterectomy is a progressive and definitive uterine fibroid procedure. For women who do not want to conceive and/or women over 40-50 years of age, in particular.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

van Voorhis B. A 41-year-old woman with menorrhagia, anemia, and fibroids: Review of treatment of uterine fibroids. JAMA. 2009;301(1):82-93. https://doi.org/10.1001/jama.2008.791 PMid:19050179 DOI: https://doi.org/10.1001/jama.2008.791

AAGL Practice Report: Practice Guidelines for the Diagnosis and Management of Submucous Leiomyomas; 2012.

Radeleff B, Eiers M, Bellemann N, Ramsauer S, Rimbach S, Kauczor HU, et al. Expulsion of dominant submucosal fibroids after uterine artery embolization. Eur J Radiol. 2010;75(1):e57-63. https://doi.org/10.1016/j.ejrad.2009.07.013 PMid:19692192 DOI: https://doi.org/10.1016/j.ejrad.2009.07.013

Younas K, Hadoura E, Majoko F, Bunkheila A. A review of evidence-based management of uterine fibroids. Obstet Gynaecol. 2016;18(1):33-42. https://doi.org/10.1111/tog.12223 DOI: https://doi.org/10.1111/tog.12223

Peitsidis P, Koukoulomati A. Tranexamic acid for the management of uterine fibroid tumors: A systematic review of the current evidence. World J Clin Cases. 2014;2(12):893-8. https://doi.org/10.12998/wjcc.v2.i12.893 PMid:25516866 DOI: https://doi.org/10.12998/wjcc.v2.i12.893

Ip PP, Lam KW, Cheung CL, Yeung MC, Pun TC, Chan QK, et al. Tranexamic acid-associated necrosis and intralesional thrombosis of uterine leiomyomas: A clinicopathologic study of 147 cases emphasizing the importance of druginduced necrosis and early infarcts in leiomyomas. Am J Surg Pathol. 2007;31(8):1215-24. https://doi.org/10.1097/pas.0b013e318032125e PMid:17667546 DOI: https://doi.org/10.1097/PAS.0b013e318032125e

Zapata LB, Whiteman MK, Tepper NK, Jamieson DJ, Marchbanks PA, Curtis KM. Intrauterine device use among women with uterine fibroids: A systematic review. Contraception. 2010;82(1):41-55. https://doi.org/10.1016/j.contraception.2010.02.011 PMid:20682142 DOI: https://doi.org/10.1016/j.contraception.2010.02.011

Kim M, Seong SJ. Clinical applications of levonorgestrel-releasing intrauterine system to gynecologic diseases. Obstet Gynecol Sci. 2013;56(2):67-75. https://doi.org/10.5468/ogs.2013.56.2.67 PMid:24327984 DOI: https://doi.org/10.5468/OGS.2013.56.2.67

Sangkomkamhang US, Lumbiganon P, Laopaiboon M, Mol BW. Progestogens or progestogen-releasing intrauterine systems for uterine fibroids. Cochrane Database Syst Rev. 2013;2:CD008994. https://doi.org/10.1002/14651858.cd008994.pub2 PMid:23450594 DOI: https://doi.org/10.1002/14651858.CD008994.pub2

Jiang W, Shen Q, Chen M, Wang Y, Zhou Q, Zhu X, et al. Levonorgestrel-releasing intrauterine system use in premenopausal women with symptomatic uterine leiomyoma: A systematic review. Steroids. 2014;86:69-78. https://doi.org/10.1016/j.steroids.2014.05.002 PMid:24832215 DOI: https://doi.org/10.1016/j.steroids.2014.05.002

Donnez J, Tatarchuk TT, Bouchard P, Puscasiu L, Nataliya F, Zakharenko T, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012;366(5):409-20. https://doi.org/10.1056/nejmoa1103182 PMid:22296075 DOI: https://doi.org/10.1056/NEJMoa1103182

Donnez J, Tomaszewski J, Vazquez F, Bouchard P, Lemieszczuk B, Baro F, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med. 2012;366(5):421-32. https://doi.org/10.1056/nejmoa1103180 PMid:22296076 DOI: https://doi.org/10.1056/NEJMoa1103180

Downloads

Published

2021-05-16

How to Cite

1.
Rusda M, Lubis AT, Hisworo MR, Rambe AYM. Submucosal Uterine Fibroid in Grand Multipara Woman: A Case Report. Open Access Maced J Med Sci [Internet]. 2021 May 16 [cited 2024 Feb. 25];9(T3):27-30. Available from: https://oamjms.eu/index.php/mjms/article/view/6317

Most read articles by the same author(s)

1 2 > >>